Detection of Previously Unidentified Structural Variants Involved in Glioblastoma Using PacBio® Sequel™ Sequencing
About the Case Study
Glioblastoma is a devastating disease due in part to its often late-stage diagnosis, rapid progression, and poor survival rates. This case study looks at how Azenta utilized the PacBio Sequel long-read technology to help a customer improve detection of structural variants within glioblastoma samples.
This case study discusses:
- Generation of thousands of long-reads using PacBio Sequel Single Molecule Real Time (SMRT) technology
- Generation of highly accurate consensus sequences
- Identification of approximately 20,000 structural variants
- Future applications